Significance of tumour cell HLA-G5/-G6 isoform expression in discrimination for adenocarcinoma from squamous cell carcinoma in lung cancer patients

Journal of Cellular and Molecular Medicine

Volumn 19, Issue 4, 2015, Pages 778-785

  Yan, Wei Hua ^a   Liu, Di ^a   Lu, Hai Yan ^a   Li, Ying Ying ^a   Zhang, Xia ^a   Lin, Aifen ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

HLA G; Non small cell lung cancer; ROC

Indexed keywords

HLA G ANTIGEN; ISOPROTEIN; TUMOR MARKER;

ADENOCARCINOMA; BIOSYNTHESIS; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DIFFERENTIAL DIAGNOSIS; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; PROGNOSIS; RECEIVER OPERATING CHARACTERISTIC; WESTERN BLOTTING;

ADENOCARCINOMA; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLOW CYTOMETRY; HLA-G ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTEIN ISOFORMS; ROC CURVE;

EID: 84925937434     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/jcmm.12400     Document Type: Article

References (30)

1. Lakshmi Narendra B, Eshvendar Reddy K, Shantikumar S, et al. Immune system: a double-edged sword in cancer. Inflamm Res. 2013; 62: 823-34.
2. Groth A, Klöss S, von Strandmann EP, et al. Mechanisms of tumor and viral immune escape from natural killer cell-mediated surveillance. J Innate Immun. 2011; 3: 344-54.
3. Kochan G, Escors D, Breckpot K, et al. Role of non-classical MHC class I molecules in cancer immunosuppression. Oncoimmunology. 2013; 2: e26491.
4. Yan WH. HLA-G expression in cancers: potential role in diagnosis, prognosis and therapy. Endocr Metab Immune Disord Drug Targets. 2011; 11: 76-89.
5. Kovats S, Main EK, Librach C, et al. A class I antigen, HLA-G, expressed in human trophoblasts. Science. 1990; 248: 220-3.
6. Yan WH. Human leukocyte antigen-G in cancer: are they clinically relevant? Cancer Lett. 2011; 311: 123-30.
7. Riteau B, Faure F, Menier C, et al. Exosomes bearing HLA-G are released by melanoma cells. Hum Immunol. 2003; 64: 1064-72.
8. Pistoia V, Morandi F, Wang X, et al. Soluble HLA-G: are they clinically relevant? Semin Cancer Biol. 2007; 17: 469-79.
9. Yan WH. HLA-G expression in hematologic malignancies. Expert Rev Hematol. 2010; 3: 67-80.
10. González A, Rebmann V, LeMaoult J, et al. The immunosuppressive molecule HLA-G and its clinical implications. Crit Rev Clin Lab Sci. 2012; 49: 63-84.
11. Lin A, Zhu CC, Chen HX, et al. Clinical relevance and functional implications for human leucocyte antigen-g expression in non-small-cell lung cancer. J Cell Mol Med. 2010; 14: 2318-29.
12. Yie SM, Yang H, Ye SR, et al. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer. 2007; 58: 267-74.
13. Yie SM, Yang H, Ye SR, et al. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol. 2007; 14: 2721-9.
14. Ye SR, Yang H, Li K, et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol. 2007; 20: 375-83.
15. Lin A, Zhang X, Zhou WJ, et al. Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Cancer. 2011; 129: 1382-90.
16. Paul P, Rouas-Freiss N, Moreau P, et al. HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expression. Hum Immunol. 2000; 61: 1177-95.
17. Sobin LH, Wittekind C, eds. TNM classification of malignant tumors. 6th ed. New York, NY: Wiley-Liss; 2002. pp. 81-3.
18. Amiot L, Ferrone S, Grosse-Wilde H, et al. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci. 2011; 68: 417-31.
19. Carosella ED, Favier B, Rouas-Freiss N, et al. Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood. 2008; 111: 4862-70.
20. Lin A, Yan WH, Xu HH, et al. HLA-G expression in human ovarian carcinoma counteracts NK cell function. Ann Oncol. 2007; 18: 1804-9.
21. Chen HX, Lin A, Shen CJ, et al. Upregulation of human leukocyte antigen-G expression and its clinical significance in ductal breast cancer. Hum Immunol. 2010; 71: 892-8.
22. Lin A, Chen HX, Zhu CC, et al. Aberrant human leucocyte antigen-G expression and its clinical relevance in hepatocellular carcinoma. J Cell Mol Med. 2010; 14: 2162-71.
23. Barrier BF, Kendall BS, Sharpe-Timms KL, et al. Characterization of human leukocyte antigen-G (HLA-G) expression in endometrial adenocarcinoma. Gynecol Oncol. 2006; 103: 25-30.
24. Gan LH, Huang LF, Zhang X, et al. Tumor-specific upregulation of human leukocyte antigen-G expression in bladder transitional cell carcinoma. Hum Immunol. 2010; 71: 899-904.
25. Schütt P, Schütt B, Switala M, et al. Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol. 2010; 71: 489-95.
26. Rebmann V, Busemann A, Lindemann M, et al. Detection of HLA-G5 secreting cells. Hum Immunol. 2003; 64: 1017-24.
27. Ugurel S, Rebmann V, Ferrone S, et al. Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer. 2001; 92: 369-76.
28. Castelli EC, Veiga-Castelli LC, Yaghi L, et al. Transcriptional and posttranscriptional regulations of the HLA-G gene. J Immunol Res. 2014; 2014: 734068.
29. Alegre E, Rizzo R, Bortolotti D, et al. Some basic aspects of HLA-G biology. J Immunol Res. 2014; 2014: 657625.
30. Loumagne L, Baudhuin J, Favier B, et al. In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. Int J Cancer. 2014; 135: 2107-17.